ALHC three-lens brief
Evidence-based stock research on ALHC. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 9% of its 52-week range — deep in the lower band.
- Trading at 9% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $10.79 — 40% above current (12 analysts).
- Reported earnings on 2026-10-29.
ALHC closed at $7.69 (+0.26%) as of 2026-11-12. Market cap: $1.61B. P/E (trailing) 54.9. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $10.79 — 40% above current (12 analysts).. Concerns: trading at 9% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $1.36B, net income -$8.05M, free cash flow $77.02M.
Why three lenses on ALHC, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ALHC across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ALHC" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ALHC brief"></iframe>